RTX Secures $24.4 Billion Missile Contract as Nasdaq Hits New High

Raytheon, a business of RTX (NYSE: RTX), secured a five-year contract with two option years worth up to $24.4 billion for Standard Missile-6 interceptors, a development that coincided with the Nasdaq Composite reaching a fresh high. The contract covers munitions used for both offensive strikes and missile defense by the U.S. Navy. Raytheon President Phil Jasper stated that the company is increasing capacity to meet demand for the multi-mission weapon, which he described as vital to the customer.

The broader market closed the week with mixed results on Oct. 5, 2026. The Nasdaq Composite rose 1.19% to a close of 27,190.86, while the Dow Jones Industrial Average fell to 51,176.96 for a weekly loss of 1.26%. The S&P 500 gained 0.73% on the day to finish at 7,722.72, though it recorded a loss for the week. The Russell 2000 index edged up 0.94% to 2,832.90 but remained down for the period.

Commodity prices showed divergence, with gold rising 0.64% to $4,189.10 an ounce and silver jumping 3.76% to $62.24. WTI crude oil slipped 0.58% to $90.58 a barrel. The 10-year Treasury yield increased by 4 basis points on the day to 5.28%, marking a weekly rise of 10 basis points.

Eli Lilly and Company (NYSE: LLY) received FDA approval for an expanded indication for Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. The approval was based on the BRUIN CLL-313 trial, where pirtobrutinib showed significantly improved progression-free survival compared to bendamustine plus rituximab, with a hazard ratio of 0.20 at a median follow-up of 28 months.

International Business Machines Corporation (NYSE: IBM) is under investigation by Hagens Berman Sobol Shapiro following a 25% share drop on July 14, 2026, which erased over $68 billion in market capitalization. CEO Arvind Krishna attributed the decline to a shortfall in Z mainframe performance and failed large deals during the second quarter.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) lowered its full-year 2026 guidance after a July flooding event at its Cincinnati facility. The company now expects third-quarter revenue of approximately $410 million to $412 million and full-year revenue of $1.634 billion to $1.654 billion.

Trilogy Metals Inc. (NYSE American: TMQ) reported a cash balance of $31.2 million as of August 31, 2026, and closed a $35.6 million strategic equity investment from the Department of War on September 11, 2026.